13 results about "Loratadine" patented technology

The present invention relates to solid compositions. The present invention addresses the problem of providing a solid composition containing at least one substance selected from the group consisting of tepiperidine and salts thereof, and at least one substance selected from the group consisting of tranexamic acid and salts thereof, in which the dissolution of tepiperidine is improved. [Solution] A solid composition containing the following components: (A) at least one substance selected from the group consisting of tepiperidine and salts thereof; (B) at least one substance selected from the group consisting of tranexamic acid and salts thereof; and (C) at least one compound selected from the group consisting of ibuprofen and salts thereof, in which the solid composition does not include a solid composition comprising levocetirizine or loratadine.

Disclosed is a pharmaceutical composition comprising loratadine and one or more pharmaceutically acceptable excipients, fruit powders, gelling agent and other additives The additives may include buffering agenting agents, binders, stabilizing agents, solubilizing agents, colorants, sweetening agents, preservatives, coating agents, flavoring agents and diluents. The present disclosure provides for loratadine, where the buccal absorption is faster as well as the active ingredients in gum can be absorbed directly through the mucous membranes in the mouth, reducing the drawbacks of the conventional gummies which encounters the challenges of very high thermal stress of the cooking process especially where the active ingredients subject to significant chemical and / or physical degradation during the manufacturing process. The present disclosure further provides a method (100) of formulating the gummy dosage pharmaceutical composition for loratadine.

The invention discloses a loratadine oral liquid and a production process thereof. Comprising the following raw materials in parts by weight: 0.5 to 0.6 part of loratadine, 5 to 6 parts of beta-cyclodextrin, 10 to 12 parts of polyethylene glycol 400, 8 to 10 parts of glycerol, 6 to 8 parts of propylene glycol, 0.3 to 0.4 part of sucralose, 0.2 to 0.3 part of stevioside, 15 to 18 parts of maltitol, 1 to 1.2 parts of citric acid, 0.5 to 0.6 part of malic acid, 0.1 to 0.15 part of disodium EDTA (Ethylene Diamine Tetraacetic Acid), 0.8 to 1 part of vitamin C, 0.3 to 0.4 part of xanthan gum, 0.5 to 0.6 part of sodium carboxymethyl cellulose and 0.4 to 0.5 part of lemon essence. The composition comprises the following components in parts by weight: 0.1-0.15 part of menthol, 2-3 parts of hawthorn extract, 1.2-1.5 parts of soya bean lecithin and the balance of purified water, totaling 100 parts. The loratadine is clathrated by the beta-cyclodextrin, the absorption promotion effect of the soya bean lecithin is combined, and the compound sweetening agent, the compound stabilizer and the natural flavor substance are matched, so that the problems of poor solubility and obvious bitter taste of the loratadine are solved, and the stability and bioavailability of the product are also improved.

The present application relates to a kind of HPLC-MS / MS detection method of detecting in human plasma, desloratadine and 3-hydroxydesloratadine in human plasma, it includes the following steps: (1) human plasma sample pretreatment;(2) liquid chromatography-mass spectrometry detection, using mobile phase A and mobile phase B as mixed mobile phase is carried out gradient elution, wherein: mobile phase A is methanol-acetonitrile mixed solution, in mixed solution methanol and acetonitrile volume ratio is 4-6:6-4;Mobile phase B is 2-20mM ammonium formate aqueous solution;(3) the determination of the concentration of human plasma in lopatadine, desloratadine and 3-hydroxydesloratadine.The present application uses lopatadine-d4, desloratadine-d5, 3-hydroxydesloratadine-d4 as deuterium internal standard, using Agilent, ZORBAX Eclipse XDB-Phenyl is carried out gradient elution, deuterium internal standard and the measured substance has the same retention time, chemical property and matrix effect, the reproducibility, accuracy of determining the concentration of lopatadine, desloratadine and 3-hydroxydesloratadine in plasma are good.The method of the present application can be used to evaluate the bioequivalence of lopatadine.

The present invention relates to solid compositions. The present invention addresses the problem of providing a solid composition containing ibuprofen in which changes in properties are suppressed. [Solution] A solid composition comprising the following components: (A) ibuprofen; (B) at least one substance selected from the group consisting of tepiperidine and salts thereof; and (C) at least one compound selected from the group consisting of tranexamic acid and salts thereof, in which the solid composition does not include a solid composition containing levocetirizine or loratadine.

The application discloses an alcohol dehydrogenase mutant and application thereof in enzymatic synthesis of a loratadine intermediate. A plurality of alcohol dehydrogenase mutants are developed, and a loratadine chiral intermediate is obtained through an enzyme catalytic synthesis method based on the mutants, wherein the reaction condition is mild, the environment is friendly, the reaction has high regional selectivity and stereoselectivity, the reaction conversion rate is high, the chiral purity of the product is high, the enzyme consumption is low, the preparation cost is low, the method is suitable for industrial production, the method avoids the problems of difficult chiral resolution and heavy metal residue in a product in a conventional method, and the method makes up for the deficiencies of a traditional chemical method.

This invention discloses a compound ointment for protecting the nasal mucosa and repairing skin damage, and its preparation method, belonging to the field of pharmaceutical technology. The compound ointment is formulated with Sophora japonica fruit extract, erythromycin ointment, vitamin B6, levofloxacin hydrochloride tablets, loratadine tablets, fluticasone propionate nasal spray, sesame oil, and honey in specific weight proportions. The components work synergistically, providing protection for the nasal mucosa, treatment of rhinitis, reduction of cold air and external pollutant intrusion, and prevention of colds. It can also treat hemorrhoids, scars, eczema, and other skin damage, achieving "one medicine for multiple uses." This compound ointment has a stable dosage form, is convenient to use, has high utilization rate, high safety, and no obvious side effects, making it suitable for various populations and possessing good industrialization prospects.

The application relates to the technical field of pharmaceutical preparations, in particular to a loratadine immediate-release tablet based on a co-micronization technology and a preparation method thereof; a pharmaceutical composition comprises a co-micronization compound, the co-micronization compound comprises loratadine and a co-micronization carrier; the application discloses a loratadine immediate-release tablet based on a co-micronization technology and a preparation method thereof, the dissolution rate and stability of the loratadine are improved by adopting the co-micronization technology and a new type of excipient combination; meanwhile, the prepared loratadine immediate-release tablet also has good in-vitro dissolution performance; the loratadine immediate-release tablet prepared by the application reduces impurity growth in the production and storage processes and obviously improves the stability of the drug; the loratadine immediate-release tablet disclosed by the application does not contain lactose in the prescription, so that the side reaction of lactose intolerance can be effectively avoided.

To provide a solid composition containing ibuprofen, the change in properties of which is suppressed. The present invention relates to a composition comprising: (A) Ibuprofen, (B) at least one selected from the group consisting of tipepidine and salts thereof, and (C) at least one selected from the group consisting of tranexamic acid and salts thereof A solid composition comprising, but excluding a solid composition comprising levocetirizine or loratadine.

To provide a solid composition containing at least one selected from the group consisting of tipepidine and salts thereof and at least one selected from the group consisting of tranexamic acid and salts thereof, which has improved dissolution properties of tipepidine. The present invention relates to a composition comprising the following components: (A) at least one selected from the group consisting of tipepidine and salts thereof, (B) at least one selected from the group consisting of tranexamic acid and salts thereof, and (C) at least one selected from the group consisting of ibuprofen and salts thereof A solid composition comprising, but excluding a solid composition comprising levocetirizine or loratadine.

An external anti-itch and anti-allergic drug after biting of biting midges and a preparation method thereof, relate to the technical field of medicine. The drug comprises: loratadine hydrochloride 0.1%-0.3%, 5%-8% lapis alumen, menthol 0.5%-1%, camphor 0.3%-0.5%, carvacrol 0.2%-0.5%, lemon eucalyptus oil 0.3%-0.6%, glycerol 3%-5%, panthenol 2%-4%, ceramide 0.1%-0.2%, vaseline 10%-15%, lanolin 5%-8%, deionized water and an appropriate amount of preservative. The preparation method comprises oil phase preparation, water phase preparation, high-speed emulsification and low-temperature mixing. Through the synergistic effect of anti-histamine components and physical anti-itch components, the multiple effects of rapid anti-itch, swelling, anti-allergy and skin barrier repair are realized, the pH value is close to the physiological environment of the skin, it is mild and non-irritating, and it is especially suitable for children, pregnant women and sensitive skin groups.

This invention belongs to the field of oral solid dosage form technology and relates to a loratadine sustained-release capsule and its preparation method. This application provides a loratadine-containing sustained-release capsule, wherein loratadine is melt-mixed with citric acid and salicylic acid to prepare a drug-containing core, and the core is coated with a sustained-release layer, an immediate-release layer, and a protective layer. This not only effectively solves the problem of slow dissolution of loratadine in the presence of insufficient gastric acid, but also ensures uniform drug release, achieving long-lasting effects and increased efficacy.

The utility model relates to the technical field of medicine extraction, in particular to an extraction device for preparing double-bond heterogeneous impurities of a loratadine intermediate. The device comprises a mixing module, an extraction module, a separation module and a control system, the mixing module, the extraction module and the separation module are sequentially connected, the control system is in communication connection with the mixing module, the extraction module and the separation module, and the mixing module comprises a high-speed stirrer and a mixing cavity. The extraction module comprises an extraction tower and a distributor, the distributor is mounted at the top of the extraction tower, the separation module comprises a centrifugal separator and a gravity settling tank, the control system comprises temperature sensors, a flow sensor and a PLC (programmable logic controller), the temperature sensors are mounted in the mixing cavity and the extraction tower, and the flow sensor is mounted in the gravity settling tank. According to the utility model, the problems of reduction of extraction efficiency and incomplete impurity separation caused by temperature fluctuation are avoided, so that the preparation quality and stability of the double-bond isomeric impurities of the loratadine intermediate are improved.